Company Overview - Zimmer Biomet Holdings, Inc. (ZBH) has a market cap of $17.8 billion and specializes in orthopedic implants and surgical solutions, with a focus on joint replacement, sports medicine, trauma, spine, and dental applications [1] - The company is headquartered in Warsaw, Indiana, and serves hospitals and surgeons globally, being particularly known for its knee and hip replacement systems and its advancements in robotic-assisted and digital surgery platforms [1] Stock Performance - Over the past year, ZBH stock has underperformed the broader market, declining 9% compared to the S&P 500 Index's 14.4% returns [2] - Year-to-date, ZBH stock has increased by 1.7%, slightly outperforming the S&P 500's 1.4% rise [2] - In comparison to the US Medical Devices Ishares ETF (IHI), which saw a 9.3% dip over the past 52 weeks, ZBH has shown better relative performance [3] Financial Performance - For fiscal 2025 Q4, Zimmer Biomet reported net sales of $2.24 billion, reflecting a year-over-year increase of 10.9%, driven by strong demand for hip and knee implants [6] - Adjusted diluted EPS for Q4 increased by 4.8% to $2.42, exceeding market expectations [6] - For the full year 2025, the company achieved $8.23 billion in revenue and announced a $1.5 billion share repurchase program [6] Future Guidance - Management has provided guidance for 2026, projecting revenue growth of 2.5% to 4.5% and adjusted EPS in the range of $8.30 to $8.45, considering near-term challenges from U.S. sales transformation [7] - Analysts expect ZBH to deliver an adjusted EPS of $8.41 for FY2026, representing a year-over-year increase of 3.1% [7] - The company has a strong earnings surprise history, having exceeded bottom-line estimates in each of the past four quarters [7] Analyst Ratings - Among 26 analysts covering ZBH stock, the consensus rating is a "Hold," which includes seven "Strong Buys," one "Moderate Buy," 15 "Holds," and three "Strong Sells" [8]